Literature DB >> 19333974

Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.

Maria Teresa Apaz1, Claudia Saad-Magalhães, Angela Pistorio, Angelo Ravelli, Juliana de Oliveira Sato, Maria Beatriz Marcantoni, Silvia Meiorin, Giovanni Filocamo, Clarissa Pilkington, Susan Maillard, Sulaiman Al-Mayouf, Sampath Prahalad, Anders Fasth, Rik Joos, Kenneth Schikler, Dagmar Mozolova, Jeanne M Landgraf, Alberto Martini, Nicolino Ruperto.   

Abstract

OBJECTIVE: To investigate the health-related quality of life (HRQOL) change over time, as measured by the Child Health Questionnaire (CHQ), and its determinants in patients with active juvenile dermatomyositis (DM).
METHODS: We assessed patients with juvenile DM at both baseline and 6 months of followup, and healthy children age < or =18 years. Potential determinants of poor HRQOL included demographic data, physician's and parent's global assessments, muscle strength, functional ability as measured by the Childhood Health Assessment Questionnaire (C-HAQ), global disease activity assessments, and laboratory markers.
RESULTS: A total of 272 children with juvenile DM and 2,288 healthy children were enrolled from 37 countries. The mean +/- SD CHQ physical and psychosocial summary scores were significantly lower in children with juvenile DM (33.7 +/- 11.7 versus 54.6 +/- 4.1) than in healthy children (45.1 +/- 9.0 versus 52 +/- 7.2), with physical well-being domains being the most impaired. HRQOL improved over time in responders to treatment and remained unchanged or worsened in nonresponders. Both physical and psychosocial summary scores decreased with increasing levels of disease activity, muscle strength, and parent's evaluation of the child's overall well-being. A C-HAQ score >1.6 (odds ratio [OR] 5.06, 95% confidence interval [95% CI] 2.03-12.59), child's overall well-being score >6.2 (OR 5.24, 95% CI 2.27-12.10), and to a lesser extent muscle strength and alanine aminotransferase level were the strongest determinants of poor physical well-being at baseline. Baseline disability and longer disease duration were the major determinants for poor physical well-being at followup.
CONCLUSION: We found that patients with juvenile DM have a significant impairment in their HRQOL compared with healthy peers, particularly in the physical domain. Physical well-being was mostly affected by the level of functional impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333974     DOI: 10.1002/art.24343

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 2.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 3.  [Dermatomyositis and juvenile dermatomyositis].

Authors:  Frank Dressler; Britta Maurer
Journal:  Z Rheumatol       Date:  2022-04-29       Impact factor: 1.372

4.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

Review 5.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 6.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

Review 7.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.

Authors:  Dragana Lazarevic; Angela Pistorio; Elena Palmisani; Paivi Miettunen; Angelo Ravelli; Clarissa Pilkington; Nico M Wulffraat; Clara Malattia; Stella Maris Garay; Michael Hofer; Pierre Quartier; Pavla Dolezalova; Inmaculada Calvo Penades; Virginia P L Ferriani; Gerd Ganser; Ozgur Kasapcopur; Jose Antonio Melo-Gomes; Ann M Reed; Malgorzata Wierzbowska; Lisa G Rider; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2012-06-26       Impact factor: 19.103

9.  2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Authors:  Rohit Aggarwal; Lisa G Rider; Nicolino Ruperto; Nastaran Bayat; Brian Erman; Brian M Feldman; Chester V Oddis; Anthony A Amato; Hector Chinoy; Robert G Cooper; Maryam Dastmalchi; David Fiorentino; David Isenberg; James D Katz; Andrew Mammen; Marianne de Visser; Steven R Ytterberg; Ingrid E Lundberg; Lorinda Chung; Katalin Danko; Ignacio García-De la Torre; Yeong Wook Song; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky
Journal:  Ann Rheum Dis       Date:  2017-05       Impact factor: 19.103

10.  Parent Perspectives on Addressing Emotional Health for Children and Young Adults With Juvenile Myositis.

Authors:  Kaveh Ardalan; Oluwatosin Adeyemi; Dawn M Wahezi; Anne E Caliendo; Megan L Curran; Jessica Neely; Susan Kim; Colleen K Correll; Emily J Brunner; Andrea M Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11-27       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.